CollPlant Biotechnologies Ltd filed a Form D with the Securities and Exchange Commission on 2026-10-22.
CollPlant Biotechnologies Ltd filed a Form D notice of an exempt securities offering with the SEC on October 22, 2026. The filing reports $9.25M sold. Its industry group is Other Health Care. It names Yehiel Tal (Chief Executive Officer and Interim Chairman of the Board of Directors), Eran Rotem (Deputy Chief Executive Officer and Chief Financial Officer), Oren Fahimipoor (Vice President, Operations) (SEC Form D, October 22, 2026).
Sell to companies like CollPlant Biotechnologies Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns CollPlant Biotechnologies Ltd.
Free to see. No signup.
More on the people and the money behind CollPlant Biotechnologies Ltd, from the filings we hold.
Other Health Care raises filed within 90 days of this one, largest first.
Get an email when CollPlant Biotechnologies Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when CollPlant Biotechnologies Ltd raises, hires or launches. No email unless you switch it on.
Watch CollPlant Biotechnologies Ltd →Get the full cited report on CollPlant Biotechnologies Ltd
What the filing shows about CollPlant Biotechnologies Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CollPlant Biotechnologies Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for CollPlant Biotechnologies Ltd →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on CollPlant Biotechnologies Ltd See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 868 filings in Other Health Care, totalled by week. The dot is this raise, $9.25M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The Company intends to use the net proceeds from the Offering for general corporate purposes including working capital and funding its research and development programs.
On the filing as: Executive Officer, Director.
Yehiel Tal is named as Chief Executive Officer and Interim Chairman of the Board of Directors on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Eran Rotem is named as Deputy Chief Executive Officer and Chief Financial Officer on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Oren Fahimipoor is named as Vice President, Operations on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Philippe Bensimon is named as Vice President, Regulatory Affairs and Quality Assurance on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Jasmine Seror is named as Vice President, Product Development on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Bowman Bagley is named as Vice President, Commercial North America on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer.
Bar Abelis is named as Vice President, Legal on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
On the filing as: Executive Officer, Director.
Ruti Ben Shlomi is named as Chief Executive Officer of Lightsolver Ltd., the Issuer's subsidiary. on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
Abraham Havron is named as Director on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
Elan Penn is named as Director on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
Joseph Zarzewsky is named as Director on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
Hugh Evans is named as Director on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
Alisa Lask is named as Director on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 22 October 2026, one of 13 people that filing names.
13 people named on the filing — 8 holding an executive role and 5 as directors only.
Named as of the 2026-10-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about CollPlant Biotechnologies Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CollPlant Biotechnologies Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CollPlant Biotechnologies Ltd covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CollPlant Biotechnologies LtdYou get an alert in MentionFox the next time this company shows up.
If you're behind CollPlant Biotechnologies Ltd: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for CollPlant Biotechnologies Ltd. With no account yet, you sign up free and land on the result.
On these lists: Health care raises, week of 2026-10-19
https://mentionfox.com/funding/collplant-biotechnologies-ltd-form-d-111756